Nektar Therapeutics

nektar.com

Nektar Therapeutics is a research-based development stage biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet medical need.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharma Tech

KIOMED PHARMA AND HANSOH PHARMA ANNOUNCE LICENSE AGREEMENT FOR KIOMEDINEVSONE IN CHINA’S MAINLAND, MACAU AND TAIWAN

KiOmed Pharma and Hansoh Pharma | September 27, 2022

news image

KiOmed Pharma, a Belgian biotechnology company with a focus on the development, manufacture and distribution of safe and effective medical devices based on a medical-grade highly pure natural chitosan-derivative, and Hansoh Pharmaceutical Group Company Limited a leading biopharmaceutical company in Asia, today announced a license agreement for the development and commercialization of KiOmedinevsOne, a carboxymethyl chitosan injection that has been launched in Europe for the treatment of knee ost...

Read More

PHARMA TECH

IDBS ANNOUNCES DATA MANAGEMENT PARTNERSHIP WITH PHARMAESSENTIA INNOVATION RESEARCH CENTER

PR Newswire | January 24, 2024

news image

IDBS announced today that it has entered into a partnership with Massachusetts-based PharmaEssentia Innovation Research Center (PIRC) on its Polar platform to help digitize data management and facilitate collaboration between the company's global research and development (R&D) teams. The Polar platform will provide PIRC, the newly established U.S. hub of PharmaEssentia's R&D efforts, the ability to electronically collaborate with its team headquartered in Taipei,...

Read More

Research

ASCENTAGE PHARMA ENTERS INTO AN AGREEMENT WITH UNIVERSITY OF MICHIGAN TO OBTAIN AN EXCLUSIVE LICENSE FOR DEGRADER

Ascentage Pharma | November 30, 2020

news image

Ascentage Pharma (6855.HK), an internationally engaged, clinical-stage biotechnology organization occupied with creating novel treatments for malignant growths, ongoing hepatitis B (CHB), and age-related infections, today reported it has gone into a concurrence with the University of Michigan, through which the organization may acquire the selective worldwide rights to a MDM2 protein degrader created utilizing the Proteolysis-Targeting Chimeras (PROTACs) innovation. The medication competitor is ...

Read More

ZEALAND PHARMA STRENGTHENS EXECUTIVE TEAM WITH NEW U.S. LEADERSHIP

Globe newswire | June 15, 2020

news image

Zealand Pharma, a biotechnology company changing lives with innovative peptide-based medicines, today announced the appointment of Frank Sanders as President of Zealand Pharma U.S. Frank will join Zealand on July 6, 2020. “I am pleased to welcome Frank Sanders to Zealand Pharma, and am confident that he will provide strong and experienced leadership for our U.S. organization,” said Emmanuel Dulac, President and Chief Executive Officer at Zealand Pharma. “Frank has more than 25 ...

Read More
news image

Pharma Tech

KIOMED PHARMA AND HANSOH PHARMA ANNOUNCE LICENSE AGREEMENT FOR KIOMEDINEVSONE IN CHINA’S MAINLAND, MACAU AND TAIWAN

KiOmed Pharma and Hansoh Pharma | September 27, 2022

KiOmed Pharma, a Belgian biotechnology company with a focus on the development, manufacture and distribution of safe and effective medical devices based on a medical-grade highly pure natural chitosan-derivative, and Hansoh Pharmaceutical Group Company Limited a leading biopharmaceutical company in Asia, today announced a license agreement for the development and commercialization of KiOmedinevsOne, a carboxymethyl chitosan injection that has been launched in Europe for the treatment of knee ost...

Read More
news image

PHARMA TECH

IDBS ANNOUNCES DATA MANAGEMENT PARTNERSHIP WITH PHARMAESSENTIA INNOVATION RESEARCH CENTER

PR Newswire | January 24, 2024

IDBS announced today that it has entered into a partnership with Massachusetts-based PharmaEssentia Innovation Research Center (PIRC) on its Polar platform to help digitize data management and facilitate collaboration between the company's global research and development (R&D) teams. The Polar platform will provide PIRC, the newly established U.S. hub of PharmaEssentia's R&D efforts, the ability to electronically collaborate with its team headquartered in Taipei,...

Read More
news image

Research

ASCENTAGE PHARMA ENTERS INTO AN AGREEMENT WITH UNIVERSITY OF MICHIGAN TO OBTAIN AN EXCLUSIVE LICENSE FOR DEGRADER

Ascentage Pharma | November 30, 2020

Ascentage Pharma (6855.HK), an internationally engaged, clinical-stage biotechnology organization occupied with creating novel treatments for malignant growths, ongoing hepatitis B (CHB), and age-related infections, today reported it has gone into a concurrence with the University of Michigan, through which the organization may acquire the selective worldwide rights to a MDM2 protein degrader created utilizing the Proteolysis-Targeting Chimeras (PROTACs) innovation. The medication competitor is ...

Read More
news image

ZEALAND PHARMA STRENGTHENS EXECUTIVE TEAM WITH NEW U.S. LEADERSHIP

Globe newswire | June 15, 2020

Zealand Pharma, a biotechnology company changing lives with innovative peptide-based medicines, today announced the appointment of Frank Sanders as President of Zealand Pharma U.S. Frank will join Zealand on July 6, 2020. “I am pleased to welcome Frank Sanders to Zealand Pharma, and am confident that he will provide strong and experienced leadership for our U.S. organization,” said Emmanuel Dulac, President and Chief Executive Officer at Zealand Pharma. “Frank has more than 25 ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us